ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.. . The ValiRx management team comprises a mix of entrepreneurial scientists who are founders of a number of medical life sciences companies and industry-specific personnel, all with extensive experience in transferring technologies and products into the commercial arena to generate revenue and growth of shareholder value.
Watch our Member Showcase Video https://bit.ly/3fB4WZq
Watch our Member Showcase Video https://bit.ly/3fB4WZq
VasoDynamics is a Stevenage and London based, clinical-stage pharmaceutical development company. We are solely focused on developing patient-friendly, cost-effective medicines to prevent the severe side-effects induced by anticancer therapies. Our programmes are designed to prevent the common complications of cancer therapy, including mouth ulceration, dermatitis, and (permanent) hair-loss. Our philosophy is to generate affordable medicines that enable cancer patients to tolerate widely used anticancer therapies, with the dual purpose of enhancing the efficacy of anti-cancer therapy and improving patients’ quality of life with cancer, without painful, traumatic or debilitating side-effects.
Venner Shipley is one of the leading firms of European patent and trademark attorneys, representing a broad range of clients including major domestic and international corporations, SMEs, universities and individual inventors. We provide a full range of services covering patents, trademarks, designs and copyright, domain names and all other aspects of intellectual property, in all areas of science, technology and design. We have a particularly strong team serving life science and healthcare companies. Our services extend beyond rights protection, to involvement in enforcement and licensing activities.
Vernalis Research develop and apply fragment and structure-based methods to solve problems in drug discovery, and have generated cell active lead compounds and development candidates against targets in oncology, neurodegeneration, anti-infectives and inflammation.
The Company balances an internal portfolio of drug discovery projects with fully integrated research collaborations on targets with pharmaceutical companies and academic partners. Its shared-risk approach ensures a high level of engagement from our scientists and rewards success. Current disclosed collaborations include those with Servier, Daiichi Sankyo, Lundbeck and Asahi Kasei Pharma, and they seek additional partnerships.
Vernalis Research also have an extensive portfolio of partnered and unpartnered drug candidates in pre-clinical and clinical development.
The Company balances an internal portfolio of drug discovery projects with fully integrated research collaborations on targets with pharmaceutical companies and academic partners. Its shared-risk approach ensures a high level of engagement from our scientists and rewards success. Current disclosed collaborations include those with Servier, Daiichi Sankyo, Lundbeck and Asahi Kasei Pharma, and they seek additional partnerships.
Vernalis Research also have an extensive portfolio of partnered and unpartnered drug candidates in pre-clinical and clinical development.
Somaserve is a UCL spin out, a uniquely positioned specialist reagent and pharma service business which exploits the proprietary polyNaut™ technology (a ‘bionic’ nanoparticle vesicle). The reagent products are highly differentiated and address an unfulfilled area in the live cell imaging market. The ‘fee for service’ offering solves molecule viability problems for clients presenting a new approach to drug discovery.
VirdisGroup is a leading executive search firm specialising in the LifeScience and Healthcare sectors. . Partnering with clients throughout the world, our focus is to identify, engage and help hire top talent from senior executive to board level. However, we support our partners in building their teams and capabilities throughout the organisation. We are respected for our strong international networks and knowledge.. We have direct experience within the following sectors:. Pharmaceutical, Biotechnology, Capital Investors, Universities, CROs, Government, Animal Health, Diagnostics, Healthcare Services, MedTech, Research Consortia, Public-Private Partnerships
No data available
VCLS is a global product development consultancy, which guides Biotechnology, Medtech, and Pharmaceutical manufacturers throughout product development and commercialization. From discovery to patients, VCLS assists innovators to design product development strategies that optimize clinical development to drive commercial success, through an understanding of both regulators and payers.
VCLS’s team of HealthTech product specialists seamlessly complement innovative life sciences companies’ resources with strategic advice and cross-functional operational capabilities. The firm offers integrated solutions to development planning, manufacturing, quality and controls, nonclinical and clinical testing, safety monitoring, and interactions with regulators and payers. With offices in Cambridge, Somerville (MA & NJ, USA), London (UK), Paris and Rennes (France), Lausanne (Switzerland), Copenhagen (Denmark) and Bangalore (India). VCLS serves a broad range of developers and investors.
VCLS’s team of HealthTech product specialists seamlessly complement innovative life sciences companies’ resources with strategic advice and cross-functional operational capabilities. The firm offers integrated solutions to development planning, manufacturing, quality and controls, nonclinical and clinical testing, safety monitoring, and interactions with regulators and payers. With offices in Cambridge, Somerville (MA & NJ, USA), London (UK), Paris and Rennes (France), Lausanne (Switzerland), Copenhagen (Denmark) and Bangalore (India). VCLS serves a broad range of developers and investors.
No data available
Our research at the Wellcome Trust Sanger Institute builds understanding of gene function in health and disease as well as creating resources of lasting value to biomedical research. . . We study diseases that have an impact on health globally by investigating genomes. Building on our past achievements and based on priorities that exploit the unique expertise of our Faculty of researchers, we will lead global efforts to understand the biology of genomes. We are convinced of the importance of making this research available and accessible for all audiences.